{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T11:33:25Z","timestamp":1792236805173,"version":"4.4.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":1009,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T00:00:00Z","timestamp":1683331200000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"IncreVet, Inc."}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bexagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. A pilot study has shown that bexagliflozin can decrease dependence on exogenous insulin in cats with diabetes mellitus (DM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the safety and effectiveness of bexagliflozin as a monotherapy for DM in previously untreated cats.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Eighty-four client-owned cats.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Historically controlled prospective open-label clinical trial. Cats were dosed PO with 15\u2009mg bexagliflozin once daily for 56\u2009days, with a 124-day extension to evaluate safety and treatment effect durability. The primary endpoint was the proportion of cats experiencing a decrease in hyperglycemia and improvement in clinical signs of hyperglycemia from baseline on day 56.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 84 enrolled cats, 81 were evaluable on day 56, and 68 (84.0%) were treatment successes. Decreases in mean serum glucose, fructosamine, and \u03b2-hydroxybutyrate (\u03b2-OHB) concentrations were observed, and investigator assessments of cat neurological status, musculature, and hair coat quality improved. Owner evaluations of both cat and owner quality of life were favorable. The fructosamine half-life in diabetic cats was found to be 6.8\u2009days. Commonly observed adverse events included emesis, diarrhea, anorexia, lethargy, and dehydration. Eight cats experienced serious adverse events, 3 of which led to death or euthanasia. The most important adverse event was euglycemic diabetic ketoacidosis, diagnosed in 3 cats and presumed present in a fourth.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and Clinical Importance<\/jats:title>\n                    <jats:p>Bexagliflozin decreased hyperglycemia and observed clinical signs in cats newly diagnosed with DM. As a once-daily PO medication, bexagliflozin may simplify management of DM in cats.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jvim.16730","type":"journal-article","created":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T05:58:27Z","timestamp":1683352707000},"page":"915-924","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Safety and effectiveness of the sodium-glucose cotransporter inhibitor bexagliflozin in cats newly diagnosed with diabetes mellitus"],"prefix":"10.1093","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0579-7587","authenticated-orcid":false,"given":"Michael J.","family":"Hadd","sequence":"first","affiliation":[{"name":"IncreVet , Boston, Massachusetts,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen E.","family":"Bienhoff","sequence":"additional","affiliation":[{"name":"Argenta , New Brunswick, New Jersey,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E.","family":"Little","sequence":"additional","affiliation":[{"name":"Bytown Cat Hospital , Ottawa, Ontario,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Geller","sequence":"additional","affiliation":[{"name":"Quakertown Veterinary Clinic , Quakertown, Pennsylvania,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Ogne-Stevenson","sequence":"additional","affiliation":[{"name":"Argenta , New Brunswick, New Jersey,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Dupree","sequence":"additional","affiliation":[{"name":"IncreVet , Boston, Massachusetts,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4736-6873","authenticated-orcid":false,"given":"J. Catharine","family":"Scott-Moncrieff","sequence":"additional","affiliation":[{"name":"Purdue University College of Veterinary Medicine Department of Veterinary Clinical Sciences, , West Lafayette, Indiana,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,5,1]]},"reference":[{"key":"2026020302564569200_jvim16730-bib-0001","doi-asserted-by":"crossref","first-page":"C14","DOI":"10.1152\/ajpcell.00388.2010","article-title":"Glucose transport by human renal Na+\/D-glucose cotransporters SGLT1 and SGLT2","volume":"300","author":"Hummel","year":"2011","journal-title":"Am J Physiol Cell Physiol"},{"key":"2026020302564569200_jvim16730-bib-0002","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1681\/ASN.2010030246","article-title":"SGLT2 mediates glucose reabsorption in the early proximal tubule","volume":"22","author":"Vallon","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"2026020302564569200_jvim16730-bib-0003","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2215\/CJN.04010609","article-title":"Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target","volume":"5","author":"Santer","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026020302564569200_jvim16730-bib-0004","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.2337\/dc19-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical Care in Diabetes-2019","volume":"42","author":"American Diabetes Association","year":"2019","journal-title":"Diabetes Care"},{"key":"2026020302564569200_jvim16730-bib-0005","doi-asserted-by":"crossref","first-page":"F188","DOI":"10.1152\/ajprenal.00518.2013","article-title":"Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia","volume":"306","author":"Rieg","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"2026020302564569200_jvim16730-bib-0006","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1007\/s00424-014-1619-7","article-title":"Localizations of Na(+)-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart","volume":"467","author":"Vrhovac","year":"2015","journal-title":"Pflugers Arch"},{"key":"2026020302564569200_jvim16730-bib-0007","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41574-020-0392-2","article-title":"Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus","volume":"16","author":"Scheen","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"2026020302564569200_jvim16730-bib-0008","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.2337\/dc18-0588","article-title":"SGLT2 inhibitors in combination therapy: from mechanisms to clinical considerations in type 2 diabetes management","volume":"41","author":"van Baar","year":"2018","journal-title":"Diabetes Care"},{"key":"2026020302564569200_jvim16730-bib-0009","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.3390\/genes11111369","article-title":"Mapping of diabetes susceptibility loci in a domestic cat breed with an unusually high incidence of diabetes mellitus","volume":"11","author":"Balmer","year":"2020","journal-title":"Genes (Basel)"},{"key":"2026020302564569200_jvim16730-bib-0010","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1146\/annurev.genom.4.070802.110436","article-title":"The inherited basis of diabetes mellitus: implications for the genetic analysis of complex traits","volume":"4","author":"Florez","year":"2003","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"2026020302564569200_jvim16730-bib-0011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0259939","article-title":"A genome-wide association study identifies novel candidate genes for susceptibility to diabetes mellitus in non-obese cats","volume":"16","author":"Forcada","year":"2021","journal-title":"PLoS One"},{"key":"2026020302564569200_jvim16730-bib-0012","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-76166-3","article-title":"Mapping the genetic basis of diabetes mellitus in the Australian Burmese cat (Felis catus)","volume":"10","author":"Samaha","year":"2020","journal-title":"Sci Rep"},{"key":"2026020302564569200_jvim16730-bib-0013","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1152\/physrev.00042.2009","article-title":"Islet amyloid polypeptide, islet amyloid, and diabetes mellitus","volume":"91","author":"Westermark","year":"2011","journal-title":"Physiol Rev"},{"key":"2026020302564569200_jvim16730-bib-0014","doi-asserted-by":"crossref","first-page":"8628","DOI":"10.1073\/pnas.84.23.8628","article-title":"Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients","volume":"84","author":"Cooper","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026020302564569200_jvim16730-bib-0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.domaniend.2020.106532","article-title":"Amyloidogenesis of feline amylin and plasma levels in cats with diabetes mellitus or pancreatitis","volume":"74","author":"Jotha-Mattos","year":"2021","journal-title":"Domest Anim Endocrinol"},{"key":"2026020302564569200_jvim16730-bib-0016","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1073\/pnas.84.11.3881","article-title":"Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells","volume":"84","author":"Westermark","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026020302564569200_jvim16730-bib-0017","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1177\/0300985815591078","article-title":"Endocrine pancreas in cats with diabetes mellitus","volume":"53","author":"Zini","year":"2016","journal-title":"Vet Pathol"},{"key":"2026020302564569200_jvim16730-bib-0018","volume-title":"The Cat: Clinical Medicine and Management","author":"Baral","year":"2012"},{"key":"2026020302564569200_jvim16730-bib-0019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0127794","article-title":"Studying cat (Felis catus) diabetes: beware of the acromegalic imposter","volume":"10","author":"Niessen","year":"2015","journal-title":"PLoS One"},{"key":"2026020302564569200_jvim16730-bib-0020","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s12020-021-02718-w","article-title":"Sodium glucose cotransporter 2 inhibitors treatment in acromegalic patients with diabetes\u2014a case series and literature review","volume":"73","author":"Zaina","year":"2021","journal-title":"Endocrine"},{"key":"2026020302564569200_jvim16730-bib-0021","first-page":"52","article-title":"Evaluation of bexagliflozin in cats with poorly regulated diabetes mellitus","volume":"86","author":"Benedict","year":"2022","journal-title":"Can J Vet Res"},{"key":"2026020302564569200_jvim16730-bib-0022","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/j.1939-1676.2010.0579.x","article-title":"Evaluation of a quality-of-life tool for cats with diabetes mellitus","volume":"24","author":"Niessen","year":"2010","journal-title":"J Vet Intern Med"},{"key":"2026020302564569200_jvim16730-bib-0023","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.2337\/dc15-0843","article-title":"Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition","volume":"38","author":"Peters","year":"2015","journal-title":"Diabetes Care"},{"key":"2026020302564569200_jvim16730-bib-0024","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12933-022-01476-x","article-title":"Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis","volume":"21","author":"Kaze","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"2026020302564569200_jvim16730-bib-0025","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/phar.1881","article-title":"SGLT2 inhibitors: a systematic review of diabetic ketoacidosis and related risk factors in the primary literature","volume":"37","author":"Burke","year":"2017","journal-title":"Pharmacotherapy"},{"key":"2026020302564569200_jvim16730-bib-0026","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1111\/dom.14075","article-title":"Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"22","author":"Liu","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"2026020302564569200_jvim16730-bib-0027","doi-asserted-by":"crossref","first-page":"E65","DOI":"10.1152\/ajpendo.00478.2010","article-title":"Induction of ketosis in rats fed low-carbohydrate, high-fat diets depends on the relative abundance of dietary fat and protein","volume":"300","author":"Bielohuby","year":"2011","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2026020302564569200_jvim16730-bib-0028","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/s41467-019-08466-w","article-title":"Dehydration and insulinopenia are necessary and sufficient for euglycemic ketoacidosis in SGLT2 inhibitor-treated rats","volume":"10","author":"Perry","year":"2019","journal-title":"Nat Commun"},{"key":"2026020302564569200_jvim16730-bib-0029","doi-asserted-by":"crossref","first-page":"882","DOI":"10.2337\/db19-1216","article-title":"The limited role of glucagon for ketogenesis during fasting or in response to SGLT2 inhibition","volume":"69","author":"Capozzi","year":"2020","journal-title":"Diabetes"},{"key":"2026020302564569200_jvim16730-bib-0030","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1080\/15563650.2017.1357824","article-title":"Retrospective review of SGLT2 inhibitor exposures reported to 13 poison centers","volume":"56","author":"Schaeffer","year":"2018","journal-title":"Clin Toxicol (Phila)"},{"key":"2026020302564569200_jvim16730-bib-0031","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2460\/javma.2001.218.38","article-title":"Efficacy of protamine zinc insulin for treatment of diabetes mellitus in cats","volume":"218","author":"Nelson","year":"2001","journal-title":"J Am Vet Med Assoc"},{"key":"2026020302564569200_jvim16730-bib-0032","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/j.1939-1676.2009.0342.x","article-title":"Field safety and efficacy of protamine zinc recombinant human insulin for treatment of diabetes mellitus in cats","volume":"23","author":"Nelson","year":"2009","journal-title":"J Vet Intern Med"},{"key":"2026020302564569200_jvim16730-bib-0033","article-title":"PROZINC\u2014Protamine Zinc Recombinant Human Insulin Injection Package Insert for Cats","author":"DailyMed"},{"key":"2026020302564569200_jvim16730-bib-0034","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1939-1676.2006.tb02851.x","article-title":"Use of glargine and lente insulins in cats with diabetes mellitus","volume":"20","author":"Weaver","year":"2006","journal-title":"J Vet Intern Med"},{"key":"2026020302564569200_jvim16730-bib-0035","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jfms.2009.05.016","article-title":"Treatment of newly diagnosed diabetic cats with glargine insulin improves glycaemic control and results in higher probability of remission than protamine zinc and lente insulins","volume":"11","author":"Marshall","year":"2009","journal-title":"J Feline Med Surg"},{"key":"2026020302564569200_jvim16730-bib-0036","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1177\/1098612X211013018","article-title":"Insulin glargine 300 U\/ml for the treatment of feline diabetes mellitus","volume":"24","author":"Linari","year":"2022","journal-title":"J Feline Med Surg"},{"key":"2026020302564569200_jvim16730-bib-0037","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jfms.2008.08.005","article-title":"Changes in blood glucose concentration are associated with relatively rapid changes in circulating fructosamine concentrations in cats","volume":"10","author":"Link","year":"2008","journal-title":"J Feline Med Surg"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/37\/3\/915\/66657326\/jvim16730.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/37\/3\/915\/66657326\/jvim16730.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T07:56:59Z","timestamp":1770105419000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/37\/3\/915\/8447803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,1]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jvim.16730","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5]]},"published":{"date-parts":[[2023,5,1]]},"assertion":[{"value":"2022-11-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}